This undated image provided by Supernus Pharmaceuticals in April 2021 shows bottles for different dosages of the drug Qelbree. On Friday, April 2, 2021, the U.S. Food and Drug Administration approved the medication for treating attention deficit hyperactivity disorder in children ages six through 17. (Supernus Pharmaceuticals via AP) health FDA OKs first new ADHD drug in over a decade for children Today 05:47 am JST Today | 06:48 am JST WASHINGTON U.S. regulators have approved the first new drug in over a decade for children with ADHD, which causes inattention, hyperactivity and impulsivity. The Food and Drug Administration OK’d Qelbree (KELL’-bree) for treating attention deficit hyperactivity disorder in children ages 6 to 17. It comes as a capsule that’s taken daily.